Scleroderma Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence LLP||商品編碼||921244|
|出版日期||內容資訊||英文 114 Pages
|硬皮症治療的全球市場:成長，趨勢，及預測 Scleroderma Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年01月01日||內容資訊: 英文 114 Pages||
Scleroderma is a rare and chronic disease that affects around 2.5 million people across the globe. The market for scleroderma therapeutics is expected to grow in the near future owing to the factors such as the rising prevalence of the disease and the focus of pharmaceutical companies to come up with novel drugs.
In the United Kingdom, around 19,000 people were diagnosed with Scleroderma in the year 2018, as stated by Scleroderma & Raynaud's UK. In the United Kingdom, Scleroderma & Raynaud's UK is the only charity which is dedicated to improving the lives of people suffering from Scleroderma in the country. Studies have suggested that the prevalence of the disease is more in the African Americans and it is 4-9 times higher in women than in men.
Currently, there has been an improvement in the treatment of scleroderma toward managing complications and providing symptomatic relief. Disease-Modifying treatment is widely being investigated for scleroderma which aims at inhibiting tissue fibrosis and vascular and immune system alterations, which are the three crucial components of disease pathogenesis. With the upcoming therapies from pharmaceutical companies and future approvals of the same will boost the growth of this market.
Scleroderma is an autoimmune disease that affects the skin, blood vessels, muscles, and internal organs. The disease is usually caused due to an abnormal immune response. Therapies for this disease include immunosuppressive drugs and in some cases, glucocorticoids.
Immunosuppressors are Expected to Witness High Growth Over the Forecast Period
There is no complete cure for Scleroderma. However, scientists have suggested a few therapies that can be useful for people suffering from this disease. Immunosuppressants are the type of medication that helps reduce the symptoms of scleroderma. As the disease is associated with the immune system, the immunosuppressants help the same by reducing the immune response from occurring. Immunosuppressors act to trigger the death of immune cells or prevent the production of more immune cells. One of the examples for immunotherapy is rituximab which reduces the level of B-cells, a type of immune cells involved in the scleroderma.
As of now, Immunosuppressants are not approved by the FDA for the treatment of scleroderma but they are given to the patients off-label. Some of the immunosuppressants used for scleroderma include Methotrexate, CellCept, Cytoxan, Imuran, cyclosporin, and Thymoglobulin. Several clinical trials are being done currently to investigate the efficacy of immunosuppressants and the results of these clinical trials have suggested that immunosuppressants can be beneficial in treating scleroderma.
Hence, with the growing clinical trials and proven efficacy of the immunosuppressants, their market is expected to grow in the future.
North America Dominates the Market
North America is expected to hold the largest share for the scleroderma therapeutics market. This is majorly attributed to the rising number of people suffering from these diseases and the developed healthcare sector which allows access to the novel therapeutics. In the United States, organizations such as Scleroderma Foundation are working towards the management of disease and research on the same. As per this foundation, Scleroderma affects about 300,000 people in the United States, about one in every thousand. It has been observed that since the last decade, scleroderma has been intensified in the United States, therefore, there is continuous research going on the country for developing a proper treatment for scleroderma. Rising clinical trials that are resulting in a positive outcome, are expected to come up with novel therapies that will boost the market growth.
The market for scleroderma therapeutics is moderately competitive and several big pharmaceutical companies are involved in the market. As there is no curative drug available, these companies are providing the drugs that reduce the symptoms of the disease. Few companies are having their products in the pipeline and few are seeking approval from the FDA. With the growing R&D focus of these companies, it is expected that novel therapies will come into the market and competition will increase in the future.